PerkinElmer

PerkinElmer, Inc. engages in the provision of products, services, and solutions for diagnostics, food, environmental, life sciences, and applied markets. It operates through the following segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment consists of technologies that help life sciences researchers better understand diseases and develop treatments. The Diagnostics segment offers instruments, reagents, assay platforms, and software to hospitals, medical labs, clinicians, and medical research professionals to help improve the health of families. The company was founded by Richard Scott Perkin and Charles W. Elmer on April 19, 1937, and is headquartered in Waltham, MA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Revvity, Inc. provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure. It focuses on translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, and informatics. With a global network and localized agility, the company serves a diverse range of organizations from pharmaceutical and biotech to clinical labs, academia, and governments. It is headquartered in Waltham, MA.

Mettler-Toledo

Waters

The Zacks Instruments - Scientific industry participants like Mettler-Toledo (MTD), Waters (WAT) and PerkinElmer (PKI) are gaining from strong life science, pharmaceutical and academic end-market demand, as well as rising healthcare spending.

3 Stocks to Watch on Rising Demand for Scientific Instruments

PerkinElmer Donation Helps Significantly Expand Capacity for Sickle Cell Disease Screening in Ghana

PerkinElmer's (PKI) latest launch is expected to enable researchers to multiplex and perform immunophenotyping and viability assays in a lesser time with a simplified user interface.

PerkinElmer's (PKI) New Benchtop Platform to Boost Workflows

WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer, Inc., (NYSE: PKI), a global leader committed to innovating for a healthier world, today launched the Cellaca® PLX Image Cytometry System, a first-of-its-kind benchtop platform that enables researchers to assess multiple Critical Quality Attributes (CQAs) of cell samples in a single automated workflow, including cell identity, quality and quantity. The cutting-edge Cellaca PLX system, designed by the company's Nexcelom unit, combines best-in-class im

PerkinElmer Unveils Industry-first Cell Analysis Solution to Streamline Cell and Gene Therapy Research and Manufacturing

PerkinElmer's (PKI) T-Cell Select reagent kit is expected to allow for a more automated workflow following the FDA's approval.

PerkinElmer's (PKI) Reagent Kit Receives FDA Clearance

WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer's (NYSE: PKI) Oxford Immunotec today announced the U.S. Food and Drug Administration (FDA) has approved the use of the T-Cell Select™ reagent kit for the automation of its T-SPOT®.TB test workflow for in vitro diagnostic (IVD) use by certified laboratories. The T-Cell Select reagent kit allows for a more automated workflow, designed to reduce hands-on time for lab personnel and lower overall costs. The increased use of automation also improves blood

PerkinElmer's Oxford Immunotec Receives U.S. FDA Approval for T-Cell Select to Automate Clinically Superior Tuberculosis Detection

PerkinElmer, Inc. (NYSE:PKI ) Baird's 2022 Global Healthcare Conference September 13, 2022 10:50 AM ET Company Participants Prahlad Singh - CEO Conference Call Participants Tom Peterson - Baird Tom Peterson Thanks, everyone. Welcome. Thank you for joining.

PerkinElmer, Inc. (PKI) Presents at Baird's 2022 Global Healthcare Conference (Transcript)

Avantor Inc.

Pacific Biosciences of California

Major U.S. indices nosedived on Sep 14 following the inflation report for the month of August.

U.S. Market Faces Worst Meltdown Since 2020: Here's Why

PerkinElmer has sold a substantial business in recent times, in order to fully focus on life science and diagnostic activities. The deal looks a bit cheap but is likely okay in the long run.

PerkinElmer: Focusing, Appealing

PerkinElmer (PKI) reported earnings 30 days ago. What's next for the stock?

PerkinElmer (PKI) Down 11.6% Since Last Earnings Report: Can It Rebound?

Thermo Fisher Scientific

You've probably never heard of them, but they're both winners.

2 Ultra-Growth Stocks to Buy Hand Over Fist and Hold Forever

Moderna

CAMBRIDGE, MA / ACCESSWIRE / August 17, 2022 / Moderna, Inc., (NASDAQ:MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that James Mock has been appointed as Moderna's Chief Financial Officer, beginning September 6, 2022. He will serve on Moderna's Executive Committee and report to Chief Executive Officer Stéphane Bancel.

James Mock Joins Moderna as Chief Financial Officer

WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer, Inc. (NYSE:PKI), a global leader committed to innovating for a healthier world, today announced that Senior Vice President and Chief Financial Officer Jamey Mock will be transitioning from the Company to pursue an outside opportunity. The Company's Board of Directors has unanimously appointed Max Krakowiak to succeed Mr. Mock as its new senior vice president and CFO, effective as of September 6, 2022. Mr. Krakowiak is currently the Company's vice pr

PerkinElmer Announces Finance Leadership Transition

Parkland Corporation (OTCPK:PKIUF) Q2 2022 Earnings Conference Call August 5, 2022 8:30 AM ET Company Participants Valerie Roberts - Director, IR Bob Espey - President & CEO Marcel Teunissen - CFO Conference Call Participants Kevin Chiang - CIBC Ben Isaacson - Scotiabank Steve Hansen - Raymond James Derek Dley - Canaccord Neil Mehta - Goldman Sachs Matthew Weekes - IA Capital Markets Michael Van Aelst - TD Securities Peter Sklar - BMO Capital Markets Luke Davis - RBC Operator Good morning. My name is Pam and I will be your conference operator today.

Parkland Corporation's (PKIUF) CEO Bob Espey on Q2 2022 Results - Earnings Call Transcript

PerkinElmer, Inc. (NYSE:PKI ) Q2 2022 Earnings Conference Call August 4, 2022 8:00 AM ET Company Participants Stephen Willoughby - VP, IR Prahlad Singh - CEO, President & Director James Mock - SVP & CFO Conference Call Participants Daniel Arias - Stifel, Nicolaus & Company Derik De Bruin - Bank of America Merrill Lynch Vijay Kumar - Evercore ISI Jack Meehan - Nephron Research Liza Garcia - UBS Paul Knight - KeyBanc Capital Markets Catherine Schulte - Robert W. Baird & Co. Joshua Waldman - Cleveland Research Company Operator Good morning.

PerkinElmer, Inc. (PKI) CEO Prahlad Singh on Q2 2022 Results - Earnings Call Transcript

It seems to have become a new trend: big, multi-divisional companies are paring down to become more focused. On Aug. 1, PerkinElmer Inc. ( PKI , Financial) hopped on the bandwagon, announcing it plans to divest its analytical, food and enterprise services businesses.

PerkinElmer: Joining the Pure Play Crowd

PerkinElmer posted its Q2 earnings with a solid set of results that prompted an upward revision of FY22 guidance. Also announced was New Mountain Capital's intention to buy a carve-out of businesses from PKI on a $2.45 billion consideration.

PerkinElmer: New Mountain Offer Worth $15.80/Share To Investors

PerkinElmer's (PKI) second-quarter results benefit from a solid performance at Discover & Analytics Solutions business.

PerkinElmer (PKI) Q2 Earnings and Revenues Surpass Estimates

PerkinElmer Inc said it will sell some of its businesses along with the brand name to private equity firm New Mountain Capital for up to $2.45 billion in cash, as it looks to focus on its life sciences and diagnostics businesses under a new name.

PerkinElmer to divest some businesses in $2.45 billion cash deal

PerkinElmer (PKI) delivered earnings and revenue surprises of 14.29% and 2.25%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

PerkinElmer (PKI) Q2 Earnings and Revenues Top Estimates

NEW YORK--(BUSINESS WIRE)--New Mountain Capital Announces Intent to Acquire PerkinElmer's Applied, Food and Enterprise Services Businesses for up to $2.45 Billion

New Mountain Capital Announces Intent to Acquire PerkinElmer's Applied, Food and Enterprise Services Businesses for up to $2.45 Billion

WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today reported financial results for the second quarter ended July 3, 2022. The Company reported GAAP earnings per share from continuing operations of $1.42, as compared to GAAP earnings per share from continuing operations of $2.19 in the same period a year ago. GAAP revenue for the quarter was $1.23 billion, as compared to $1.23 billion in the same period a year ago.

PerkinElmer Announces Financial Results for the Second Quarter of 2022

WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced it has entered into an agreement with the intention to divest its Applied, Food and Enterprise Services businesses to New Mountain Capital, a leading growth-oriented private equity firm, for total consideration of $2.45 billion in cash, $2.30 billion of which will be received at the closing and $150 million of which will be payable contingent on the exit

PerkinElmer Accelerates Transformation into High Growth, High Margin Life Sciences & Diagnostics Company

PerkinElmer (PKI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: PerkinElmer (PKI) Q2 Earnings Expected to Decline

WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer, Inc., a global leader committed to innovating for a healthier world, today announced that a placental growth factor (PlGF) measurement using its DELFIA® Xpress PlGF 1-2-3TM kit (CE-IVD) and a soluble fms-like tyrosine kinase 1 (sFlt-1)/PlGF ratio using its DELFIA® Xpress sFlt-1 kit (CE-IVD), have been included in an updated diagnostic guidance issued by the United Kingdom's National Institute for Health and Care Excellence (NICE) to help diagnose su

News for PerkinElmer Stock (PKI)